Vascular compliance is secured under angiotensin inhibition in non-diabetic chronic kidney diseases

ABSTRACT Cardiovascular diseases constitute major cause of death in chronic kidney diseases (CKDs). We examined the effects of angiotensin inhibition either with angiotensin-converting

enzyme inhibitor or with angiotensin receptor blocker on patient prognosis and heart-ankle pulse wave velocity (haPWV) in CKDs. Randomized controlled study was performed on 102 patients with

non-diabetic CKDs. Patients were divided into two groups with or without angiotensin inhibition, and followed until death, creatinine clearance was halved or starting renal replacement

therapy, whichever occurred first. For 4 years, haPWV was assessed repeatedly in the surviving patients. While both groups showed well blood pressure control throughout 4 years (129±1 to

131±2/71±1 to 73±2 mm Hg), renal prognosis was better in angiotensin inhibition group (_P_<0.05). In addition, angiotensin inhibition reduced cardiovascular and renal death (_P_<0.05).

Age, sex, heart rate, systolic blood pressure and proteinuria were correlated to haPWV (_R_2=0.76, _P_<0.0001). Although haPWV was similar between two groups at the start of the study

(1098±31 vs 1094±37 cm/s), it was higher in patients without angiotensin inhibition than that with angiotensin inhibition 4 years later (1034±38 cm/s (_n_=28) vs 1242±37 cm/s (_n_=23),

_P_<0.01). The present results provided the evidence that angiotensin inhibition arrested a time-dependent elevation of haPWV in non-diabetic CKDs, conferring organ protection.

Furthermore, our data indicated that angiotensin inhibition improved patient prognosis in non-diabetic chronic kidney diseases with mild-to-moderate renal dysfunction. Access through your

institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12

digital issues and online access to articles $119.00 per year only $9.92 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices

may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support

SIMILAR CONTENT BEING VIEWED BY OTHERS CURRENT USE OF ANGIOTENSIN II RECEPTOR BLOCKERS AND ANGIOTENSIN-CONVERTING ENZYME INHIBITORS FOR HYPERTENSION IN PATIENTS WITH CHRONIC KIDNEY DISEASE

WITH PROTEINURIA: A CROSS-SECTIONAL STUDY BASED ON REAL-WORLD DATA Article 19 September 2024 CENTRAL AORTIC PRESSURE AND LONG-TERM OUTCOME IN HYPERTENSIVE PATIENTS UNDERGOING PERCUTANEOUS

CORONARY INTERVENTION Article Open access 15 October 2020 DIFFERENTIAL IMPACT OF ANTIHYPERTENSIVE DRUGS ON CARDIOVASCULAR REMODELING: A REVIEW OF FINDINGS AND PERSPECTIVES FOR HFPEF

PREVENTION Article 08 October 2021 REFERENCES * The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline

in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. _Lancet_ 1997; 349: 1857–1863. Article  Google Scholar  * Brenner BM, Cooper ME, de

Zeeuw D, Keane WF, Mitch WE, Parving HH, _et al_., RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. _N

Engl J Med_ 2001; 345: 861–869. Article  CAS  PubMed  Google Scholar  * Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G _et al_. Angiotensin-converting enzyme inhibitors and

progression of nondiabetic renal disease. A meta-analysis of patient-level data. _Ann Intern Med_ 2001; 135: 73–87. Article  CAS  PubMed  Google Scholar  * Jafar TH, Stark PC, Schmid CH,

Landa M, Maschio G, de Jong PE, _et al_., AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme

inhibition: a patient-level meta-analysis. _Ann Intern Med_ 2003; 139: 244–252. Article  CAS  PubMed  Google Scholar  * Bidani AK, Griffin KA . The benefits of renin-angiotensin blockade in

hypertension are dependent on blood-pressure lowering. _Nat Clin Pract Nephrol_ 2006; 2: 542–543. Article  PubMed  Google Scholar  * Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton

B, Hamm LL _et al_. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease,

High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. _Circulation_ 2003; 108: 2154–2169. Article  PubMed  Google Scholar  * Jungers P, Khoa TN, Massy ZA,

Zingraff J, Labrunie M, Descamps-Latscha B _et al_. Incidence of atherosclerotic arterial occlusive accidents in predialysis and dialysis patients: a multicentric study in the Ile de France

district. _Nephrol Dial Transplant_ 1999; 14: 898–902. Article  CAS  PubMed  Google Scholar  * Patient Registration Committee, Japanese Society for Dialysis Therapy, Tokyo. An overview of

regular dialysis treatment in Japan (as of 31 December 2002). _Ther Apher Dial_ 2004; 8: 358–382. Article  Google Scholar  * Nakamura T, Kanno Y, Takenaka T, Suzuki H, for the Efficacy of

Candesartan on Outcome in Saitama Trial (E-COST) Group. An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal

insufficiency. _Hypertens Res_ 2005; 28: 415–423. Article  CAS  PubMed  Google Scholar  * O'Hare AM, Glidden DV, Fox CS, Hsu CY . High prevalence of peripheral arterial disease in

persons with renal insufficiency: results from the National Health and Nutrition Examination Survey 1999–2000. _Circulation_ 2004; 109: 320–323. Article  PubMed  Google Scholar  * Takenaka

T, Takahashi K, Kabayashi T, Oshima E, Iwasaki S, Suzuki H . Oxidized low-density lipoprotein as a marker of atherosclerosis in hemodilaysis patients. _Clin Nephrol_ 2002; 58: 33–37. Article

  CAS  PubMed  Google Scholar  * Bakris GL . Angiotensin-converting enzyme inhibition to enhance vascular health—clinical and research models. _Am J Hypertens_ 2001; 14: 264S–269S. Article 

CAS  PubMed  Google Scholar  * Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, _et al_., LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan

Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. _Lancet_ 2002; 359: 995–1003. Article  CAS  PubMed  Google Scholar  * Guerin AP,

Blacher J, Pannier B, Marchais SJ, Safar ME, London GM . Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. _Circulation_ 2001; 103: 987–992. Article

  CAS  PubMed  Google Scholar  * Blacher J, Asmar R, Djane S, London GM, Safar ME . Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. _Hypertension_

1999; 33: 1111–1117. Article  CAS  PubMed  Google Scholar  * Safar ME, Levy BI, Struijker-Boudier H . Current perspectives on arterial stiffness and pulse pressure in hypertension and

cardiovascular diseases. _Circulation_ 2003; 107: 2864–2869. Article  PubMed  Google Scholar  * Yamashina A, Tomiyama H, Takeda K, Tsuda H, Arai T, Hirose K _et al_. Validity,

reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. _Hypertens Res_ 2002; 25: 359–364. Article  PubMed  Google Scholar  * Takenaka T,

Kobayashi K, Suzuki H . Pulse wave velocity as an indicator of arteriosclerosis in hemodialysis patients. _Atherosclerosis_ 2004; 176: 405–409. Article  CAS  PubMed  Google Scholar  *

Nakamura U, Iwase M, Nohara S, Kanai H, Ichikawa K, Iida M . Usefulness of brachial-ankle pulse wave velocity measurement: correlation with abdominal aortic calcification. _Hypertens Res_

2003; 26: 163–167. Article  PubMed  Google Scholar  * Imanishi R, Seto S, Toda G, Yoshida M, Ohtsuru A, Koide Y _et al_. High brachial-ankle pulse wave velocity is an independent predictor

of the presence of coronary artery disease in men. _Hypertens Res_ 2004; 27: 71–78. Article  PubMed  Google Scholar  * Gibbons GH, Dzau VJ . The emerging concept of vascular remodeling. _N

Engl J Med_ 1994; 330: 1431–1438. Article  CAS  PubMed  Google Scholar  * Kato H, Suzuki H, Tajima S, Ogata Y, Tominaga T, Sato A _et al_. Angiotensin II stimulates collagen synthesis in

cultured vascular smooth muscle cells. _J Hypertens_ 1991; 9: 17–22. Article  CAS  PubMed  Google Scholar  * Pagano PJ, Chanock SJ, Siwik DA, Colucci WS, Clark JK . Angiotensin II induces

p67phox mRNA expression and NADPH oxidase superoxide generation in rabbit aortic adventitial fibroblasts. _Hypertension_ 1998; 32: 331–337. Article  CAS  PubMed  Google Scholar  * Cockcroft

DW, Gault MH . Prediction of creatinine clearance from serum creatinine. _Nephron_ 1976; 16: 31–41. Article  CAS  PubMed  Google Scholar  * Suzuki H, Nakamoto H, Okada H, Sugahara S, Kanno Y

. Self-measured systolic blood pressure in the morning is a strong indicator of decline of renal function in hypertensive patients with non-diabetic chronic renal insufficiency. _Clin Exp

Hypertens_ 2002; 24: 249–260. Article  CAS  PubMed  Google Scholar  * Takenaka T, Itaya Y, Suzuki H . Young hemodialysis patients are exposed to hyperhomocysteinemia. _J Ren Nutr_ 2005; 15:

435–440. Article  PubMed  Google Scholar  * McDonald DA . Regional pulse-wave velocity in the arterial tree. _J Appl Physiol_ 1968; 24: 73–78. Article  CAS  PubMed  Google Scholar  * Michel

JB, Heudes D, Michel O, Poitevin P, Philippe M, Scalbert E _et al_. Effect of chronic ANG I-converting enzyme inhibition on aging processes. II. Large arteries. _Am J Physiol_ 1994; 267:

R124–R135. Article  CAS  PubMed  Google Scholar  * Atkinson J, Tatchum-Talom R, Corman B . Effect of chronic ANG I-converting enzyme inhibition on aging processes. III. Endothelial function

of mesenteric arterial bed of rat. _Am J Physiol_ 1994; 267: R136–R143. CAS  PubMed  Google Scholar  * Wang MC, Tsai WC, Chen JY, Huang JJ . Stepwise increase in arterial stiffness

corresponding with the stages of chronic kidney disease. _Am J Kidney Dis_ 2005; 45: 494–501. Article  PubMed  Google Scholar  * Hirata K, Vlachopoulos C, Adji A, O'Rourke MF . Benefits

from angiotensin-converting enzyme inhibitor ‘beyond blood pressure lowering’: beyond blood pressure or beyond the brachial artery? _J Hypertens_ 2005; 23: 551–556. Article  CAS  PubMed 

Google Scholar  * Takenaka T, Mimura T, Kanno Y, Suzuki H . Qualification of arterial stiffness as a risk factor to the progression of chronic kidney diseases. _Am J Nephrol_ 2005; 25:

417–424. Article  PubMed  Google Scholar  * Okada H, Inoue T, Kanno Y, Kobayashi T, Watanabe Y, Kopp JB _et al_. Interstitial fibroblast-like cells express renin-angiotensin system

components in a fibrosing murine kidney. _Am J Pathol_ 2002; 160: 765–772. Article  CAS  PubMed  PubMed Central  Google Scholar  * Hisada Y, Sugaya T, Yamanouchi M, Uchida H, Fujimura H,

Sakurai H _et al_. Angiotensin II plays a pathogenic role in immune-mediated renal injury in mice. _J Clin Invest_ 1999; 103: 627–635. Article  CAS  PubMed  PubMed Central  Google Scholar  *

Asmar RG, London GM, O'Rourke ME, Mallion JM, Romero R, Rahn KH, _et al_., REASON Project Investigators (pREterax in regression of Arterial Stiffness in a contrOlled double-bliNd

Study). Amelioration of arterial properties with a perindopril-indapamide very-low-dose combination. _J Hypertens_ 2001; 19: S15–S20. Article  CAS  Google Scholar  * Garg JP, Ellis R,

Elliott WJ, Hasabou N, Chua D, Chertow GM _et al_. Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study. _Am J Nephrol_ 2005; 25: 393–399. Article 

CAS  PubMed  Google Scholar  * Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G . Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in

high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. _N Engl J Med_ 2000; 342: 145–153. Article  CAS  PubMed  Google Scholar  * Banerjee D, Brincat S, Gregson H,

Contreras G, Streather C, Oliveira D _et al_. Pulse pressure and inhibition of renin-angiotensin system in chronic kidney disease. _Nephrol Dial Transplant_ 2006; 21: 975–978. Article  CAS

  PubMed  Google Scholar  * Tozawa M, Iseki K, Iseki C, Takishita S . Pulse pressure and risk of total mortality and cardiovascular events in patients on chronic hemodialysis. _Kidney Int_

2002; 61: 717–726. Article  PubMed  Google Scholar  * Takenaka T, Suzuki H . New strategy to attenuate pulse wave velocity in hemodialysis patients. _Nephrol Dial Transplant_ 2005; 20:

811–816. Article  PubMed  Google Scholar  * Amann K, Wolf B, Nichols C, Tornig J, Schwarz U, Zeier M _et al_. Aortic changes in experimental renal failure: hyperplasia or hypertrophy of

smooth muscle cells? _Hypertension_ 1997; 29: 770–775. Article  CAS  PubMed  Google Scholar  Download references ACKNOWLEDGEMENTS We thank Chieko Yanagitate and Maiko Toma for their

excellent secretarial help during the preparation of this manuscript. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Nephrology, Saitama Medical College, Iruma, Saitama, Japan T

Mimura, T Takenaka, Y Kanno, K Moriwaki, H Okada & H Suzuki Authors * T Mimura View author publications You can also search for this author inPubMed Google Scholar * T Takenaka View

author publications You can also search for this author inPubMed Google Scholar * Y Kanno View author publications You can also search for this author inPubMed Google Scholar * K Moriwaki

View author publications You can also search for this author inPubMed Google Scholar * H Okada View author publications You can also search for this author inPubMed Google Scholar * H Suzuki

View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to H Suzuki. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT

THIS ARTICLE CITE THIS ARTICLE Mimura, T., Takenaka, T., Kanno, Y. _et al._ Vascular compliance is secured under angiotensin inhibition in non-diabetic chronic kidney diseases. _J Hum

Hypertens_ 22, 38–47 (2008). https://doi.org/10.1038/sj.jhh.1002264 Download citation * Received: 25 October 2006 * Revised: 09 March 2007 * Accepted: 24 March 2007 * Published: 26 July 2007

* Issue Date: January 2008 * DOI: https://doi.org/10.1038/sj.jhh.1002264 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link

Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative KEYWORDS * angiotensin * blood

pressure * cardiovascular disease * creatinine clearance * pulse wave velocity